Tags

Type your tag names separated by a space and hit enter

Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate.
Am J Obstet Gynecol. 1989 May; 160(5 Pt 2):1296-300.AJ

Abstract

Three new 19-nortestosterone progestogens, which are chemically related to levonorgestrel, are now clinically available in combination oral contraceptives in Europe. Desogestrel and norgestimate must be transformed to metabolites for all or part of their biologic activity; gestodene is active in its original form. Compared with present low-dose monophasic and triphasic levonorgestrel formulations, the new combinations appear to be equivalent in efficacy and type and frequency of side effects. Cycle control may be slightly improved with the gestodene preparation and somewhat poorer with the desogestrel regimen. As with the present triphasics, most changes reported in coagulation indexes for the new combinations remained within normal limits, as did changes in carbohydrate and lipid metabolism. There is no present evidence that either the norgestimate or aesogestrel formulation provides a clinical improvement over the levonorgestrel triphasic. In the gestodene combination, the progestogen's increased biologic activity allows further reduction of total steroid dose.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School.

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

2524163

Citation

Chez, R A.. "Clinical Aspects of Three New Progestogens: Desogestrel, Gestodene, and Norgestimate." American Journal of Obstetrics and Gynecology, vol. 160, no. 5 Pt 2, 1989, pp. 1296-300.
Chez RA. Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate. Am J Obstet Gynecol. 1989;160(5 Pt 2):1296-300.
Chez, R. A. (1989). Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate. American Journal of Obstetrics and Gynecology, 160(5 Pt 2), 1296-300.
Chez RA. Clinical Aspects of Three New Progestogens: Desogestrel, Gestodene, and Norgestimate. Am J Obstet Gynecol. 1989;160(5 Pt 2):1296-300. PubMed PMID: 2524163.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical aspects of three new progestogens: desogestrel, gestodene, and norgestimate. A1 - Chez,R A, PY - 1989/5/1/pubmed PY - 1989/5/1/medline PY - 1989/5/1/entrez KW - Biology KW - Clinical Research KW - Contraception KW - Contraceptive Agents KW - Contraceptive Agents, Estrogen KW - Contraceptive Agents, Female KW - Contraceptive Agents, Progestin KW - Contraceptive Methods KW - Corpus Luteum Hormones KW - Economic Factors KW - Endocrine System KW - Ethinyl Estradiol KW - Family Planning KW - Hormones KW - Levonorgestrel KW - Metabolic Effects KW - Oral Contraceptives KW - Oral Contraceptives, Combined KW - Physiology KW - Progestational Hormones KW - Progesterone KW - Reproductive Control Agents KW - Research And Development KW - Research Methodology KW - Technology SP - 1296 EP - 300 JF - American journal of obstetrics and gynecology JO - Am J Obstet Gynecol VL - 160 IS - 5 Pt 2 N2 - Three new 19-nortestosterone progestogens, which are chemically related to levonorgestrel, are now clinically available in combination oral contraceptives in Europe. Desogestrel and norgestimate must be transformed to metabolites for all or part of their biologic activity; gestodene is active in its original form. Compared with present low-dose monophasic and triphasic levonorgestrel formulations, the new combinations appear to be equivalent in efficacy and type and frequency of side effects. Cycle control may be slightly improved with the gestodene preparation and somewhat poorer with the desogestrel regimen. As with the present triphasics, most changes reported in coagulation indexes for the new combinations remained within normal limits, as did changes in carbohydrate and lipid metabolism. There is no present evidence that either the norgestimate or aesogestrel formulation provides a clinical improvement over the levonorgestrel triphasic. In the gestodene combination, the progestogen's increased biologic activity allows further reduction of total steroid dose. SN - 0002-9378 UR - https://www.unboundmedicine.com/medline/citation/2524163/Clinical_aspects_of_three_new_progestogens:_desogestrel_gestodene_and_norgestimate_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9378(89)80016-X DB - PRIME DP - Unbound Medicine ER -